Non-invasive Tool to Screen Non-alcoholic Fatty Liver Disease

A diagnostic model that is highly predictive of nonalcoholic fatty liver disease (NAFLD) referred to as the Framingham Steatosis Index (FSI), may become a cheaper and easier alternative to screen for liver fat.

With the increasing rates of obesity, NAFLD is now the most common chronic liver disease in the United States, with 10-35 percent of the general population affected. Other risk factors for NAFLD include type 2 diabetes mellitus, elevated triglycerides and the metabolic syndrome.

Currently, the diagnosis of NAFLD requires evidence of hepatic steatosis (fatty liver) on computed tomography (CT) scans or liver biopsy - both of which are costly, burdensome and impractical to implement on a large scale.

‘a set of predictors of hepatic steatosis that includes age, gender, hypertension, triglyceride levels, diabetes and the ratio of AST:ALT correlated with NAFLD.’

NAFLD has been linked to developing advanced liver and cardiovascular disease. With such a large population at risk for NAFLD, there is an urgent need for non-invasive tools to assist clinicians in diagnosing NAFLD.

Using data from the Framingham Heart Study (FHS) researchers performed a cross-sectional study of more than 1,000 members of the Framingham Third Generation Cohort. FHS participants with fatty liver disease were identified by abdominal CT scans.

Researchers evaluated a comprehensive list of demographic, clinical and laboratory parameters including liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the ratio of AST:ALT to identify people with hepatic steatosis.

The data was analyzed to find a set of predictors of hepatic steatosis. The researchers found that a model that includes age, gender, hypertension, triglyceride levels, diabetes and the ratio of AST:ALT correlated with NAFLD. The FSI was then externally validated and was found to be an effective surrogate diagnostic index for NAFLD. The findings appear in the journal Clinical Gastroenterology and Hepatology.

"Clinically, the FSI may be useful to help identify NAFLD patients or those at high risk for steatosis who may benefit from abdominal imaging. Additionally, the ALT:AST ratio may be considered a useful surrogate for hepatic steatosis (versus either ALT or AST alone) especially for future population-based studies," explained corresponding author Michelle Long, MD, assistant professor of medicine at Boston University School of Medicine (BUSM), who is also a gastroenterologist at Boston Medical Center (BMC).

Source: Eurekalert

Fatty Liver Disease: A Growing Health Problem in India

Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.

Fibroscan for Fatty Liver Cirrhosis and Fibrosis

Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to estimate the degree of fatty infiltration in the liver.

Alcoholic Liver Disease

Encyclopedia section of medindia gives general information about Alcoholic Liver Disease.

Current Treatments for Liver Cancer

Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early.

Hepatitis A

Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. Hepatitis A vaccine is available that is 95% effective in preventing the disease.

Living Donor Liver Transplant: What Are the Risks?

The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk of morbidity is anywhere between 1.3% (in highly experienced centers) to 60%.